Penny Traders Club

[samsamsamiam]

https://www.justice.gov/criminal-vns/united-states-v-jason-nielsen

https://www.sec.gov/litigation/complaints/2020/comp24832.pdf

[Scotttrader80]

Whats the latest among this gang of thieves?


https://www.sec.gov/litigation/complaints/2020/comp24832.pdf

[Sobek]

$HQGE .0006

Very nice merger news announced yesterday with company doing $3 million in annual sales

Within minutes after the news came out, filings hit to go current

They have only $485k in liabilities and over $5 million in hard assets

https://www.otcmarkets.com/stock/HQGE/news/HQ-Global-Education-Inc-Acquires-1oneninety5-LLC?id=256228

https://www.zoominfo.com/c/1oneninety5/399122274

85% OF COMMONS INSIDER OWNED

FLOAT 800m AS OF 3/6/2020

HIGHEST ALL TIME HISTORIC VOLUME DAY ONLY 83m

NO R/S HISTORY

Was trading strong in the .002 range before it was way oversold

A small group got in on it at the 52 week low but a bigger, stronger group could take it by storm imo

[Scotttrader80]

DGTW, get some

[Gold prospector]

Check out this video on ARYC about half way down page!

https://allergycarecenters.org/

[Gold prospector]

Huge news on ARYC! Arrayit production team commences $27.9 million microarray manufacturing run to build inventory for our clinical network offering physician-ordered allergy testing services as personalized medicine tools to improve allergy patient healthcare and wellness arrayit.com/Services/servi…

[Sobek]

Hi PTC! I'm doing good. How you been?

[Sobek]

STAU if you can get the CEO to play ball.

[Scotttrader80]

Anymore tips of undervalued plays? WINMQ and ARYC have turned out to be JUNK.

[Gold prospector]

Congratulations to the longs holding ARYC!

[Scotttrader80]

Didnt get any $WINMQ .05's yet but Im Not UNDERWATER like the .31-.43's are.

Boy oh boy those .43's were a lousy call

[MGStocks]

Wrong so far

[PennyStock Alert]

Thank you for the update. $1.42 Billion last quarter and trading this low? Yes, please

[Scotttrader80]

Breakout!?, $WINMQ more like a Breakdown. This is going LOWER

[Gold prospector]

PennyTradersClub has Windstream Holdings https://www.windstream.com/about/windstream-information/company-overview on watch for a massive breakout from the current share price of .37/share. We believe that this company is incredibly undervalued at any share price under $20/share. We see the following from the last Quartly report (10Q):

Total revenue and sales:
$1.420 Billion
[$5.6 Billion annualized]

Total cost of sales:
$1.345 Billion
[$5.3 Billion annualized]

Net income:
$ 41.3 million
[$165 million annualized]

Yes, you read that correctly: Net income of $41.3 million ... last quarter alone! $1.42 Billion in sales ... last quarter alone!

Again, we believe that Windstream is incredibly undervalued at this level (share price has a historical high of $112/share)

A few points:
1. Shareholders and share structure remains intact.
2. There will be no change in share structure whatsoever.
3. This is a voluntary restructuring, not a Chapter 7.
4. Insiders are buying https://www.sec.gov/Archives/edgar/data/1282266/000122520818008610/xslF345X03/doc4.xm

Buying at this level should be an opportunity to build massive gains. Please review the links below:

https://investor.windstream.com/news/news-details/2019/Windstream-Holdings-Inc-Files-for-Voluntary-Reorganization-Under-Chapter-11-of-the-US-Bankruptcy-Code-Following-Judge-Furmans-Decision/default.aspx

https://en.wikipedia.org/wiki/Chapter_11,_Title_11,_United_States_Code

https://www.sec.gov/Archives/edgar/data/1282266/000128226618000052/a2018093010q.htm

https://www.windstream.com/about/windstream-information/company-overview

http://news.windstream.com/news-releases/news-release-details/windstream-holdings-inc-files-voluntary-reorganization-under

https://www.sec.gov/Archives/edgar/data/1282266/000128226618000033/a2017form11-k.htm

https://www.instagram.com/windstream_talent

$WIN Windstream receives approval of motions to support normal business operations https://t.co/ujfvKIJzQg pic.twitter.com/ZS5mX1fBzi

— Windstream (@Windstream) February 26, 2019

?



Report TOS
Moderate

[Scotttrader80]

The Q hits Wednesday, EVERY media rag covering the last BK-Q will be on this like vultures on road kill.

Todays .37 cents may see single digits by FRYday

Im looking for .05 cents

[Scotttrader80]

The Q hits Wednesday, EVERY media rag covering the last BK-Q will be on this like vultures on road kill.

Todays .37 cents may see single digits by FRYday

Im looking for .05 cents

[Scotttrader80]

I'll place a order for .05 cents

[PennyStock Alert]

.20 puts Market Cap for WIN at $9 Million. As nice as that would be to load up on a couple million shares there, I don’t see it getting that low. If it does, they will be devoured IMO

[Scotttrader80]

I dont think the market is done taking WIN down. Once the Q hits Wednesday that'll trigger more eyes and the tutes will definatley take notice.

Fundamentally WIN is a solid company, so whenever this controversy subsides, they should regain past numbers.

That would be explosive for anyone who bought in under .20 cents

[Gold prospector]

PennyTradersClub has Windstream Holdings https://www.windstream.com/about/windstream-information/company-overview on watch for a massive breakout from the current share price of .37/share. We believe that this company is incredibly undervalued at any share price under $20/share. We see the following from the last Quartly report (10Q):

Total revenue and sales:
$1.420 Billion
[$5.6 Billion annualized]

Total cost of sales:
$1.345 Billion
[$5.3 Billion annualized]

Net income:
$ 41.3 million
[$165 million annualized]

Yes, you read that correctly: Net income of $41.3 million ... last quarter alone! $1.42 Billion in sales ... last quarter alone!

Again, we believe that Windstream is incredibly undervalued at this level (share price has a historical high of $112/share)

A few points:
1. Shareholders and share structure remains intact.
2. There will be no change in share structure whatsoever.
3. This is a voluntary restructuring, not a Chapter 7.
4. Insiders are buying https://www.sec.gov/Archives/edgar/data/1282266/000122520818008610/xslF345X03/doc4.xm

Buying at this level should be an opportunity to build massive gains. Please review the links below:

https://investor.windstream.com/news/news-details/2019/Windstream-Holdings-Inc-Files-for-Voluntary-Reorganization-Under-Chapter-11-of-the-US-Bankruptcy-Code-Following-Judge-Furmans-Decision/default.aspx

https://en.wikipedia.org/wiki/Chapter_11,_Title_11,_United_States_Code

https://www.sec.gov/Archives/edgar/data/1282266/000128226618000052/a2018093010q.htm

https://www.windstream.com/about/windstream-information/company-overview

http://news.windstream.com/news-releases/news-release-details/windstream-holdings-inc-files-voluntary-reorganization-under

https://www.sec.gov/Archives/edgar/data/1282266/000128226618000033/a2017form11-k.htm

https://www.instagram.com/windstream_talent

$WIN Windstream receives approval of motions to support normal business operations https://t.co/ujfvKIJzQg pic.twitter.com/ZS5mX1fBzi

— Windstream (@Windstream) February 26, 2019

[Gold prospector]

VSYM up 65% this morning!

[Gold prospector]

View System, Inc (VSYM) a concealed weapons detection & security company.

ViewScan Original:

Locates and Visually Indicates Threat Objects

Adjustable Audible Alarm

Reduces False Alarms

Faster Throughput than Conventional Metal Detectors

Safe for Medical Devices such as Pacemakers

Easily Movable

Easy to use Intuitive Graphical User

Interface (GUI)

Image and Data Archiving

Optional 4-Hour Battery (sold separately)

Quickly Prints Evidence (printer sold separately)

Seamlessly Integrates with View’s Positive

ID Management System (sold separately)

Weighs only 56 lbs (75lbs shipping weight)

Camera can be mounted to unit as shown (instead of a separate camera which must be installed across from the unit on the walls of the facility)

http://viewsystems.com/VS/products/access-control-systems



Now in addition to all that...

The new superior “ViewScan II” will be the “Swiss Army Knife” of walk through detectors incorporating a multiple of sensing devices.

Facial recognition, airborne chemicals, radiation detection, “sniffer” technologies and record keeping of individuals coming and going are just some of the comprehensive capabilities. Self contained, battery operated, portable with wireless communication to a central network makes this THE security detector of choice. The “ViewScan II” is the first such “smart” portal to enter the market. View is readying this superior product to enter the security market in 2019.

https://finance.yahoo.com/news/view-systems-inc-announces-product-144058653.html



The CEO, Gunther Than, can confirm that things are moving along nicely for the company especially with this new superior product that’s getting ready to enter the market in the first quarter of 2019.

Stay tuned for additional updates & press releases!

The new superior “ViewScan II” is a new product and is different from the old product, which used the same name in the past (over a decade ago). I know that some folks on the board questioned the similar name, but a simple glance of this new product will give you the impression that this is definitely the future of security technology.

Here’s a good email to confirm the above information or simply to email the CEO requesting additional information...

[e-mail]



“ViewScan” product demo:

http://viewsystems.com/VS/video-demos



Key points as to why the “ViewScan” technology is superior from the competition:


Passive Technology

* It does not generate or emit any radiation what so ever.

* Being safe for everyone who walks through it.


Having a picture of everyone who walks through it.


Laptop controlled

* Being able to look at the screen & pin point where the items are visually.


Network Connectivity

* Being able to connect multiple view scans together as well as tie to your existing surveillance system.



$VSYM pink current information:

https://www.otcmarkets.com/stock/VSYM/news



Big partnerships in the works... View Systems, Inc has ties to PRG Potomac River Group who does a lot of business with several government agencies.

http://www.prgusa.net/about-us/



View Systems’ products are currently installed in the United States in schools, correctional facilities, law enforcement facilities, and a variety of federal agencies and have been or are being used by the SEC, IRS and Secret Service. The original View Scan has been used by the national affiliations such as NFL’s Super Bowl, MLB’s All Star Games and National Democratic Committee conventions.

[trading.jeff]

$ARYC .08 tapped, HOD.

[Gold prospector]

NEW PR...Arrayit Corporation Announces In-Network Allergy Testing Services Contract with a Top Five Commercial Healthcare Benefits Company http://bit.ly/2GIkriW

[Gold prospector]

Welcome Kaboom!

[KABOOM_TIME]

Hi everyone!

[Gold prospector]

Final Alert update on SHLDQ (2-2-19) and expected 8K on Tuesday:

Hope you are having a great New Year and the Market is treating you well ?? a quick update on Sears/Kmart [OTCBB: SHLDQ] and the updated $5.2 Billion accepted buyout (see link) received last week and pending acceptance on Monday:

This stock [OTC: SHLDQ] is both Sears and Kmart. Please review the links at the bottom from recent 8Ks. There has been an active and confirmed Short Attack that brought the SHLDQ from $140+/share down to under .40/share and volatility brought it to where it is now (.54/share) but with a reversal and last weeks announcement of a buyout for $5.2 Billion and news coming next week, we believe that SHLDQ will head back over $47/share.

There are now over 600 Kmart and Sears stores in operation in the United States with over 50,000 employees. Sears and Kmart are currently undergoing restructuring under Chapter 11 to rebuild, keep the 425 most profitable stores, and with assets of over $3 billion, this SHLDQ market cap of $58 million is unbeatable by any other pennystock.

A few facts:

SHLDQ has Outstanding Shares of less than 109 million

Float of less than 30 million shares

Market Cap of $58 million

SHLDQ insiders own over 70% of the 109 million OS

With chapter 11 restructuring, we expect that the over 600 stores nationwide will return SHLDQ back to $47+ per share.

https://www.reuters.com/article/us-sears-pensions/u-s-agency-seeks-approval-to-take-over-sears-pensions-idUSKCN1PQ5US?il=0

https://www.latimes.com/business/la-fi-sears-20190109-story.html

https://www.cnbc.com/2019/01/09/eddie-lampert-reportedly-submits-revised-bid-of-roughly-5-billion-to-save-sears-from-liquidation.html

https://finance.yahoo.com/news/lampert-said-ready-higher-bid-165137897.html

https://www.cnbc.com/2019/01/08/chairman-eddie-lampert-to-get-another-chance-to-save-sears-sources-say.html

[Scotttrader80]

VYST do a little due

[Gold prospector]

$ARYC clinical sales team announces enrollment of Kaiser Permanente in our Patient Data Solutions allergy testing portal providing on-line test kits, test reports and immunotherapy options for allergy and asthma doctors in one of the nation's top HMOs patientdatasolutions.com/signup/rs4884/

[Gold prospector]

Just a reminder please continue to hold ARYC you won’t regret it! We are expecting NASDAQ in 2019 huge opportunity will create generation wealth for all of us!

[Gold prospector]

Congratulations to those that got into CBBT! Nice profits!

[Gold prospector]

VNUE is a new pick! Entry .0044 area we could see copper easily ~105M float

[Gold prospector]

PTCers it’s a good time to get back in SHLDQ coming out of BK!

[Scotttrader80]

$INTV follows Crypto currency, Just completed re-AUDITING their 2017 2018 10 K's due to Accountants PCAOB reprimand, awaiting Q1 2019 should be filed this coming week.

Definately one for your watchlist, dont wait too long in taking a potition. When BTC turns around INTV follows.

[Gold prospector]

PTCers keep an eye on SHLDQ on Monday we could see the start to a nice run!

[StockDetective]

Patent & NIH clinical trials for Arrayit Corp (ARYC) major microarray product line pending FDA approval.


Spiriplex like AllergyPro is one of Arrayit’s marketing partners.


Spiriplex Patent: Method and device for allergy testing and treatment.

https://patents.google.com/patent/WO2016179402A1/en

https://www.freshpatents.com/-dt20161110ptan20160327567.php

Methods of applying proteins to surfaces to form arrays are well known. The immobilization may be covalent or noncovalent, via a linker moiety, or tethering to an immobilized moiety. These methods are well known in the field of solid phase synthesis and micro-arrays, for example as described in Beier et al., Nucleic Acids Res. 27:1970-1-977 (1999), and U.S. Pat. No. 6,101,946 to Martinsky. Examples include binding moieties for attaching proteinaceous molecules to a solid support include streptavidin or avidin/biotin linkages, carbamate linkages, ester linkages, amide, thiolester, (N)-functionalized thiourea, functionalized maleimide, amino, disulfide, amide, hydrazone linkages, and among others. Furthermore, a number of companies offer commercial services for preparing protein arrays, for example Arrayit Corporation (Sunnyvale, Calif.). Preferably, the source of the proteins is an extract of the allergen source, such as those available from GREER® Allergy Immunotherapy (Lenoir, N.C.). Preferably, the extract of the allergen source is standardized.

Aspects of the inventions described herein have been described on the website of ARRAYIT® Corporation (arrayit.com) and links thereon. All such disclosures were made by another who obtained the subject matter disclosed directly or indirectly from the inventor of the present application.




1-2-18: Arrayit completes site visit and laboratory tour with a key business-to-business B2B partner and regulatory consultant regarding submission of a proprietary microarray product line to the United States Food and Drug Administration for FDA clearance https://www.fda.gov


Allergenex/Spiriplex:

http://spiriplex.com/


Spiriplex/AllergyPro

http://allergypro.us/wp-content/uploads/2016/09/ICD-9-to-ICD-10-Codes.pdf




1-3-18 Arrayit advanced microarray technology to be incorporated into a clinical trial by a major pharmaceutical giant in a development that could significantly increase revenues and earnings in 2018 arrayit.com/Products/products.html


United Allergy Services sponsoring Spiriplex.


https://clinicaltrials.gov/ct2/show/NCT03514303




National Institutes of Health: Arrayit submits capabilities statement for major microarray services contract with National Institutes of Health NIH nih.gov

3-21-18: Arrayit sales and marketing team receives $1,050,000 genomics and proteomics pre-solicitation announcement from top government agency National Institutes of Health NIH headquartered in Bethesda Maryland USA and operating with a $31.3 billion annual budget https://www.nih.gov

Arrayit government contracts team reports $440,000 sample testing solicitation from the world leader Department of Health and Human Services National Cancer Institute NCI headquartered in Bethesda Maryland USA and supported by a $5.4 billion annual budget (link: https://www.cancer.gov) cancer.gov



NIH first posted May 2, 2018

* Note: Arrayit Corp (ARYC) began releasing press releases once again in May 2018.

http://arrayit.com/Arrayit_Corporation_ARYC_Corpo/Microarray_Media_-_Press/microarray_media_-_press.html



7-16-2018: Arrayit Corporation Reports Clinical Instrumentation Sale to the United States Food and Drug Administration

http://arrayit.com/Arrayit_Corporation_ARYC_Corpo/Microarray_Media_-_Press/Arrayit_Corporation_Reports_Cl/arrayit_corporation_reports_clinical_instrumentation_sale_to_the.html


9-24-2018: Arrayit Corporation Ships Clinical Instrumentation and Software to the United States Food and Drug Administration

http://arrayit.com/Arrayit_Corporation_ARYC_Corpo/Microarray_Media_-_Press/Arrayit_Corporation_Ships_Clin/arrayit_corporation_ships_clinical_instrumentation_and_software_.html

https://www.fpds.gov/ezsearch/fpdsportal?q=arrayit&s=FPDSNG.COM&templateN=&&templateName=1.5.1&indexName=awardfull


Arrayit Corp (ARYC) Has firmed several immunotherapy partnerships & several clinics have recently enrolled in their Patient Data Solutions allergy testing portal, therefore, one could also easily form the opinion that we are in phase III of the clinical trials & about to enter the final step


A Phase III trial gathers more information about safety and effectiveness, studying different populations and different dosages, using the drug in combination with other drugs. The number of subjects usually ranges from several hundred to about 3,000 people. If the FDA agrees that the trial results are positive, it will approve the experimental drug or device.
A Phase IV trial for drugs or devices takes place after the FDA approves their use. A device or drug's effectiveness and safety are monitored in large, diverse populations. Sometimes, the side effects of a drug may not become clear until more people have taken it over a longer period of time.

https://www.nia.nih.gov/health/what-are-clinical-trials-and-studies



Further, below are the Medicare Coverage policies along with Arrayit Corp (ARYC) press release a few days before entering the NIH clinical trials.

Effective September 19, 2000, clinical trials that are deemed to be automatically qualified are:

1. Trials funded by NIH, CDC, AHRQ, CMS, DOD, and VA;

2. Trials supported by centers or cooperative groups that are funded by the NIH,
CDC, AHRQ, CMS, DOD and VA;

3. Trials conducted under an investigational new drug application (IND) reviewed
by the FDA; and

4. Drug trials that are exempt from having an IND under 21 CFR 312.2(b)(1) will be
deemed automatically qualified until the qualifying criteria are developed and the certification process is in place. At that time the principal investigators of these trials must certify that the trials meet the qualifying criteria in order to maintain
Medicare coverage of routine costs. This certification process will only affect the future status of the trial and will not be used to retroactively change the earlier deemed status.

https://www.cms.gov/Medicare/Coverage/ClinicalTrialPolicies/downloads/finalnationalcoverage.pdf




Arrayit Corporation Announces New Clinical Licensure from the Centers for Medicare and Medicaid Services

Sunnyvale, May 09, 2018 (GLOBE NEWSWIRE) -- Arrayit Corporation (OTC: ARYC), a life sciences and personalized medicine company, announces receipt of a new clinical licensure from the Centers for Medicare and Medicaid Services (CMS), which oversees the Clinical Laboratory Improvement Amendments (CLIA) Program. Arrayit’s new CLIA license, issued in conjunction with the Department of Health and Human Services (HHS) and the California Department of Public Health (CDPH), provides certification for its Silicon Valley clinical laboratory.

http://arrayit.com/Arrayit_Corporation_ARYC_Corpo/Microarray_Media_-_Press/Arrayit_Corporation_Announces_/arrayit_corporation_announces_new_clinical_licensure_from_the_ce.html

[Gold prospector]

?Congratulations to those that got in $SHLDQ we received good news!?? Watch for gap in the morning!?

[Gold prospector]

$ARYC Microarray product line has been submitted to the FDA & now pending approval.


1-2-18: Arrayit completes site visit and laboratory tour with a key business-to-business B2B partner and regulatory consultant regarding submission of a proprietary microarray product line to the United States Food and Drug Administration for FDA clearance https://www.fda.gov


Allergenex/Spiriplex:

Microarray finger stick allergy testing clinical trials...

https://clinicaltrials.gov/ct2/show/NCT03514303

Start date of clinical trials was May2018.

Completion date of clinical trials is February 2019.

Sponsor United Allergy Services located in San Antonio Texas.

https://www.unitedallergyservices.com/united-allergy-services-about/

https://allergyfreesolutions.com/item/microarraytechnology/

http://spiriplex.com/allergies/


Arrayit business development team reports revenues and earnings expansion opportunity with a leading allergy testing clinic headquartered in San Antonio Texas USA and serving the massive health and wellness allergy and asthma testing services markets (link: http://arrayit.com/Clinical/clinical.html) arrayit.com/Clinical/clini…

Arrayit business development team reports revenues and earnings expansion opportunity with a leading allergy testing clinic headquartered in San Antonio Texas USA and serving the massive health and wellness allergy and asthma testing services markets https://t.co/TRfj3lWfRd pic.twitter.com/CZdPimKrtf

— Arrayit Corporation (@arrayit) January 3, 2019

Arrayit Corporation Ships Clinical Instrumentation and Software to the United States Food and Drug Administration

https://www.yahoo.com/amphtml/finance/news/arrayit-corporation-ships-clinical-instrumentation-093000351.html


https://www.fpds.gov/ezsearch/fpdsportal?q=arrayit&s=FPDSNG.COM&templateN=&&templateName=1.5.1&indexName=awardfull



Market’s first high-performance blood card technology... Blood card technology is pending 510(k) submission and is not to be used for in vitro diagnostics prior to FDA approval.

http://www.arrayit.com/Microarray_Diagnostics/Blood_Cards/blood_cards.html



510(k) Clearance to Market:

The majority of Class II medical devices are cleared to market by submission and FDA review of a 510(k) Pre-Market Notification submission. The 510(k) submission identifies characteristics of the new or modified medical device as compared to a medical device with similar intended use, currently legally marketed in the United States. The currently legally marketed device is referred to as the “predicate” device.

Depending on the complexity of the new or modified medical device, the FDA Review of a 510(k) submission takes between 20 and 90+ days. The more complex the changes or comparison required to support the safety and effectiveness of the new or modified medical device, the longer the FDA review process.

http://www.qrasupport.com/FDA_MED_DEVICE.html


See the similarities :)

http://spiriplex.com/science/

[StockDetective]

ARYC
The CEO Letter to Shareholders summarizes company accomplishments during a dynamic 2018 fiscal year and outlines ambitious goals for 2019.

http://arrayit.com/Arrayit_Corporation_ARYC_Corpo/Microarray_Media_-_Press/Arrayit_Corporation_Announces_/arrayit_corporation_announces_chief_executive_officer_letter_to_.html

http://www.arrayit.com/confidential/Letter-to-Arrayit-Shareholders.pdf




Recent email response:

“The financials are right on schedule, following the industry standard 8-12 weeks per fiscal year. Based on the excellent progress, we decided to file all of the 10-Ks and 10-Qs at the same time, rather than one fiscal year at a time. The total time to complete the audit is the same as always. Our web team will update the web to reflect the CEO Letter to Shareholders' timeline of filing in the first quarter of 2019. Thanks, Mark”




Financials are imminent...

February 14, 2019 deadline for the 2018 Q3 financial statements for Delinquent Filers...

https://www.skadden.com/-/media/files/publications/2018/12/2018yearendchecklist.pdf?la=en



ARYC stock is about to go parabolic IMO :)

[Gold prospector]

PTCers $FTEG ~218 million float! CBD pet industry and ECO cleaning Products and future merger coming up! Run up into pennies possible in the near future!

[Gold prospector]

ARYC
AllergyPro is the only company to use the same proteins for blood testing, scratch testing and immunotherapy in the world.

https://s3.amazonaws.com/bbemail/PROD/ulib/p5d1n/docs/73d0e7a8-72f3-5203-445b-dfea5f12a989/HMAllergyProSales11.12.16.pdf


LabPharm subsidiary Allergy Labs of America...


For over 10 years, Allergy Labs of America has specialized specifically in the Allergy Testing and Treatment services. ALA is an Ancillary service company offered from our parent company LabPharm LLC.

LabPharm has over 50,000 physicians currently utilizing services offered. ALA Works with a vast network of these clinics to provide a gold standard of healthcare to patients, promote higher education, and innovation within our field.

Our Goal is to provide patients a more effective, safe, and healthy alternative to help your patients end their suffering from allergies. We are passionate about this goal, which is clearly seen in the quality of the service we provide to patients, and staff alike.

http://www.allergylabsofamerica.com/about-us/

[Gold prospector]

$NSPX .006 CAN IT RUN TO OVER $3?

$NSPX .006?! WAS 55 CENTS. CANCER PATENT GRANTED NOT PR'ed. UNKNOWN. If you ever heard about $NSPX chances are you heard it from ME.

https://patents.justia.com/assignee/inspyr-therapeutics-inc

$NSPX HUGE Merger. NOT PR'D????
https://globenewswire.com/news-release/2017/09/13/1120305/0/en/Inspyr-Therapeutics-and-Lewis-and-Clark-Pharmaceuticals-Complete-Merger.html

Only 9 MILLION shares outstanding?

YOU guys KNOW how pharma stocks run from subs to $$$ ranges. $NSPX has a patent signed a $100 million private financing already received 25 million. Its A lotto for me but I like her. You see on the L2 after .02 is $200, THIN. Only reason its down at this mouth watering price is because it is VERY UNKNOWN. Won't be unknown for long

This is a little sloppy write up. Just little items I connected together. Trying to simplify the DD.

$NSPX Secures Patent on Methods of Producing Cancer Targeting

Inspyr Therapeutics Secures Patent on Methods of Producing Cancer Targeting CompoundsPharmaceutical | Tue 19 Dec 2017Alexandria, Dec. 19 -- Inspyr Therapeutics has secured a patent on methods of producing cancer targeting compounds. Lynch John K, Hutchison Jeff, #$%$ Xiong and Kunnen Kevin developed the invention. The patent application number is 15/232,599. The International Patent Classification codes are C07D 307/93 (20060101), C07C 227/16 (2..

"INSPYR THERAPEUTICS AND LEWIS AND CLARK PHARMACEUTICALS MERGE"

"Lewis & Clark Pharma: We have deep expertise in the synthesis, analysis, and early stage development of adenosine receptor-based compounds, with a focus on A2A and A2B antagonists, and A2A agonists. Our proprietary compounds are highly potent and selective, and – most importantly, have molecular properties that enable enhanced distribution in tissue and penetration of human skin – and the opportunity for novel therapies that could address a broad range of large, chronic, underserved diseases:

A2A/A2B antagonists for a range of tumors, as a mono- or combination therapy, including:

Solid tumors, e.g., breast, colorectal, melanoma, lung, prostate, bladder

Hematological malignancies, e.g., multiple myelomas, acute lymphocyte leukemia"

From the annual report from fiscal year ending December 31, 2016: Our major focus for the next twelve to eighteen months is the (i) development of a clinical protocol for and enrollment into a dose optimization trial of single-agent mipsagargin followed by a clinical trial in patients with advanced HCC, (ii) completion of the non-clinical study of mipsagargin in combination with Nexavar® in liver tumor models (iii) development of a Phase 1b clinical protocol of mipsagargin in combination with Nexavar® in patients with Nexavar® naïve HCC in anticipation of positive non-clinical data, (iv) completion of a nonclinical study of mipsagargin in combination with paclitaxel and in combination with DC101 (Cyramza surrogate antibody) in gastric cancer tumor models, (v) ongoing business development discussions with potential development partners, (vi) evaluation of mipsagargin (single agent and in combination with standard of care) in nonclinical models of other solid tumor types that express PSMA, (vii) evaluate our PSMA-peptide prodrug technology with new linkers and new payloads in non-clinical models, and (viii) explore collaborations utilizing mipsagargin in new, non-clinical solid tumor models with leading researchers in the oncology field.

Proceeds will be used to advance Inspyr’s clinical development plans and provide for working capital needs. The Company’s entry into the Milost Equity Subscription Agreement Financing Facility (MESA) and the initial tranche of funding is subject to required approvals, final documentation, and customary closing conditions.

“We are pleased to have reached an agreement on the key investment terms, the first step in securing a solid foundation of capital for Inspyr for the next several years,” said Peter Grebow, Ph.D., Chairman of Inspyr Therapeutics.

“We are pleased to be a financial partner to Inspyr and look forward to closing the transaction promptly,” said Egerton Forster, Milost Global Inc. Co-found

NSPX RECENTLY SECURED
100M in financing from private equity firm, the needle is moving in the right direction.

"Well...I see that they have started a couple trials involving treatment with sorafenib with mipsigargin as an adjuvant therapy.
Hmmmmmmmmmmmmmmmmm...they say they are looking for a synergistic effect from the combo. The non pre clinical trial will be used on folks with advanced HCC, so they are looking for arresting progression of the disease. Mipsigargin was a lot better at arresting progression than sorafenib's 2 months. Perhaps together they can arrest progression for a year or more. I suspect that even with progression arrested, many folks will die as a result of the damage the cancer has already caused.

Hey...the company is moving forward again. Cheers for the new year!!!"

Can $NSPX run over $3? Its a cancer pharma stock with patents. 1 succesful trial away from $100+ imo. You know how these pharmas go. Hit or miss.
NSPX NSPX NSPX NSPX NSPX NSPX NSPX NSPX
NSPX NSPX NSPX NSPX NSPX NSPX NSPX NSPX
NSPX NSPX NSPX NSPX NSPX NSPX NSPX NSPX
NSPX NSPX NSPX NSPX NSPX NSPX NSPX NSPX
NSPX NSPX NSPX NSPX NSPX NSPX NSPX NSPX
NSPX NSPX NSPX NSPX NSPX NSPX NSPX NSPX
NSPX NSPX NSPX NSPX NSPX NSPX NSPX NSPX
NSPX NSPX NSPX NSPX NSPX NSPX NSPX NSPX



Report TOS

[Gold prospector]

Sunnyvale, Nov. 19, 2018 (GLOBE NEWSWIRE) -- Arrayit Corporation (OTC: ARYC), a life sciences and personalized medicine company, announces an allergy testing agreement with Northern California healthcare leader Sutter Health. The company is providing its proprietary microarray-based finger stick allergy testing services to Sutter Health via doctors in the Sutter Health-affiliated Palo Alto Medical Foundation. Sutter Health, one of the nation’s largest healthcare networks, is headquartered in Sacramento California and has 50,000 employees including 12,000 physicians and 14,000 nurses serving 3 million Northern California patients. Sutter Health draws 19% of its revenue from the California Medical Assistance Program (Medi-Cal) and reports total patient service revenues of $12,000,000,000 ($12 billion) annually.

[PennyStock Alert]

ARYC

Arrayit on-line company Store sales exceed $55.5 million all-time on 226,285 microarray products and services sold

twitter.com/arrayit

Arrayit Corporation on Facebook

Please DD and research what's about to happen here.

http://www.arrayit.com/

A list of Arrayit Corporation patents:
https://t.co/EMXlE743rz

A link to their products:

http://www.arrayit.com/Products/products.html

Get in now my friends :)

[Gold prospector]

$ETII Just a few things we have:

1. CBD Energy Shots
2. BCAA+CBD Post Workout Powder
3. CBD Brownies
4. CBD+Hemp Protein Powder
5. CBD Oil cartridges
6. CBD Micro Dose Spray
7. CBD Gummies
8. CBD Capsules
9. CBD Syrup
10. CBD Oil for Food/Drinks/Vapes
11. CBD Pet Line ***Coming Soon***

[Gold prospector]

CYBF is a low floater ready to run

[PennyStock Alert]

For all new shareholders of $ARYC please read:

Website:
http://www.arrayit.com/

Check out their Facebook page: Arrayit Corporation

Follow $ARYC on Twitter @Arrayit

Arrayit completes strategic conference call with $183.9 billion pharmaceutical giant Novartis NYSE:NVS Cambridge MA https://www.novartis.com

Arrayit reports Parkinson's Disease Test PDx™ partnering opportunity with top physician in Molecular Medicine India (link: http://nimhans.ac.in) nimhans.ac.in
Arrayit reports $350,000 microarray services inquiry from leading Veterans Administration Health Care Palo Alto CA paloalto.va.gov

ARYC reports partnership opportunity with $655M healthcare manufacturing leader Quidel Nasdaq:QDEL San Diego Ca

ARYC: $8,000,000+ in sales in 2016
Incredibly undervalued. Please DD

@Arrayit
http://www.arrayit.com/

$24.4 million contract just signed

ARYC also owns 34 million shares of AVDX.

Arrayit's corporate headquarters, located at 927 Thompson Place, Sunnyvale, California, 94085, feature 15,000 square feet of modern industrial space including 45 parking spaces, offices, conference rooms, demonstration laboratories, class 100 cleanrooms, and manufacturing and shipping facilities.
Arrayit new company newsletter to feature our popular microarray-based genotyping services for biomedical research arrayit.com/Services/SNP_G…

Arrayit receives $168,000 letter of credit from top microarray technology and life science distributor in South Asia
(link: http://arrayit.com/Products/products.html)
arrayit.com/Products/produ…

Arrayit receives new financing lead that could generate 6,000 x $100K = $600MM in Arrayit microarray platform sales
http://
arrayit.com

Arrayit reports 1,000 whole blood collection card sale to to research lab in Southern US
http://
arrayit.com/Products/Prote
in_Microarrays/Blood_Card/blood_card.html
…

Arrayit reports $15K microarray sale to top medical Stephenson Cancer Center Oklahoma City
http://
stephensoncancercenter.org


Arrayit Store sales exceed $54 million all-time on 222,269 microarray products and services
http://
shop.arrayit.com

?pic.twitter.com/HbVEPj4bMX?

Arrayit reports $18,500 microarray platform sale life sciences leader ChemBio Moscow Russia
?http://www.?
?chembio.ru?

Arrayit quotes $160,000 microarray platform to molecular diagnostic leader Akonni Biosystems
http://www.
akonni.com

Arrayit production team expands blood card manufacturing to 10,000 units per week to meet microarray research demand
http://
arrayit.com/Products/Prote
in_Microarrays/Blood_Card/blood_card.html
…

Arrayit customers at Axo Science Lyon France use Arrayit microarray platform to ID bladder cancer prevention markers
http://
arrayit.com/Publications/b
ladder-cancer-prevention.pdf
…

Arrayit reports microarray technology sale to top nanotechnology healthcare leader Sonanutech Davis CA
http://
sonanutech.net

Arrayit reports microarray technology sale to world diagnostics leader Ventana Medical Sysytems Roche Tucson AZ
http://www.
ventana.com

Arrayit contact top Wells Fargo analyst Tim Evans explains revenue/earnings synergies in life science & diagnostics
http://
arrayit.com/Wells-Fargo-16
1114.pdf
…

Arrayit ships $35K proprietary microarray platform to leading European distributor Grupo Taper Mem Martins Portugal
http://www.
taper.es

Arrayit reports microarray technology sale to agricultural biotechnology leader Microgaia Biotech Murcia Spain
http://
microgaia.eu

Arrayit reports $10K microarray technology sale to world proteomics leader CDI Laboratories located in Baltimore MD
http://
cdi-lab.com

Arrayit featured in Global DNA Microarray Market Research Report 2016 with top molecular DX companies GE and Cepheid
http://www.
reportsnreports.com/reports/732130
-global-dna-microarray-market-research-report-2016.html
…

Arrayit designs custom microarray technology platform for top wellness testing company located in the European Union
http://
arrayit.com/Products/Micro
array_Platforms/microarray_platforms.html
…

Arrayit customers at the Korea Research Institute use the Arrayit microarray platform to publish biosensors advance
http://
pubs.acs.org/doi/abs/10.102
1/acs.analchem.6b02071
…

Arrayit confirms site visit business development meeting with advanced genomics leader Genomic Vision Bagneux France
http://www.
genomicvision.com

Arrayit SpotBot® Extreme Microarray Spotter newsletter receives 3,265 hits on life sciences tools segment strength
http://
arrayit.com/Products/Micro
arrayers/Microarray_Spotter/microarray_spotter.html
…

Arrayit reports $200,000 microarray platform inquiry from top life sciences leaders AH Diagnostics Aarhus Denmark
http://www.
ahdiagnostics.dk

Arrayit reports $34K microarray instrument sale to top European Union life sciences distributor European Biotech Network Dolembreux Belgium.

Arrayit equity research contact Tim Evans Wells Fargo illustrates 15-quarter strength of venture capital investing in biotechnology sector.
Arrayit signs 3-year $24.4 million patented microarray technology sales and marketing agreement with a leading laboratory services provider.

Arrayit customers from Arizona State use Arrayit microarray technology to publish adult stem cell therapy advance
http://www.
sciencedirect.com/science/articl
e/pii/S1873506115000598
…

Can an antibody microarray made with Arrayit technology replace in-situ hybs in HER2 breast cancer diagnostics?...
?http://?
?fb.me/2Xx9b1Oom?

Arrayit quotes $179,430 microarrays to biomedical leader Progenie Molecular Valencia España
http://www.
progenie-molecular.com



Arrayit quotes $51,680 microarrays to top leader De La Salle University Manila Philippines
http://www.
dlsu.edu.ph


Arrayit quotes $102,240 microarray platform to venture think tank Leading Technology Group
http://www.
leadingtechnology.co

Arrayit quotes $38,485 microarray platform to top Korean distributor Daemyung Science Seoul
http://www.
dm4you.com


Arrayit Corporation ??@arrayit?
Arrayit completes conference call on huge DNA testing opportunity in massive market in India
http://
arrayit.com/Services/SNP_G
enotyping/snp_genotyping.html
…

Arrayit reports DNA testing inquiry from top agency in India. Market penetration of 0.1% would produce $48M revenues
http://
arrayit.com/Services/SNP_G
enotyping/snp_genotyping.html
…

Arrayit Corporation ??@arrayit?
Arrayit quotes $235,000 microarray instruments to top lab University Ottawa Ontario Canada
http://www.
uottawa.ca

Arrayit reports microarray sale to advanced technology leaders Waki Company Tokyo Japan
http://
waki-bg.jp

Arrayit reports microarray sale to automated molecular testing leader AutoGenomics Vista CA
?http://www.?
?autogenomics.com?

Arrayit reports microarray sale to life sciences European Biotech Network Dolembreux Belgium
?http://www.?
?euro-bio-net.com?

Arrayit reports microarray sale to top medical researcher at $13.4B endowed MIT Cambridge MA
http://
web.mit.edu

Arrayit expands marketing on $100K+ TissueMax™ Automated and Personal Tissue Microarrayers
Arrayit reports $400,000 microarray instruments inquiry from top European Union distributor
http://
arrayit.com/Products/Micro
arrayers/Microarray_Printers/microarray_printers.html
…

Arrayit invited to appear on Business Television BTV hosted by broadcast partner Bloomberg
?http://www.?
?b-tv.com?

Arrayit $17.7MM OvaDx® spin-off and 6,000 diagnostic test pipeline possibility emphasizes the $17.7MM x 6,000 = $106B ARYC market potential.

Arrayit reports $9K chemical sale in specialty trading subsidiary TeleChem International Inc
http://www.
telecheminternational.com



Arrayit reports $100K microarray inquiry Al Rayyan International Science Center Amman Jordan
https://www.
linkedin.com/in/nader-ghana
yem-3b1306a2?authType=NAME_SEARCH&authToken=ofog&locale=en_US&srchid=2270647621456852532077&srchindex=1&srchtotal=2&trk=vsrp_people_res_photo&trkInfo=VSRPsearchId%3A2270647621456852532077%2CVSRPtargetId%3A365047477%2CVSRPcmpt%3Aprimary%2CVSRPnm%3Atrue%2CauthType%3ANAME_SEARCH
…

[Gold prospector]

ETII is our next play called at .32 expecting $1 or more!

[Gold prospector]

Arrayit manufacturing team completes $1.65 million microarray manufacturing run to build inventory for a major customer commercializing our innovative and non-invasive finger stick microarray allergy test to assist doctors in treating allergy and asthma arrayit.com/Clinical/Aller…